Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06218056 · ClinicalTrials.gov registry record · Phase 2
Cannabidiol for Reducing Cigarette Use
A Phase 2 study of Tobacco Use Disorder and Tobacco Smoking, sponsored by University of California, Los Angeles.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 120
- Enrollment target
- 1
- Study location
NCT06218056 is a Phase 2 study of Tobacco Use Disorder and Tobacco Smoking that is actively recruiting participants, run by University of California, Los Angeles. The registered enrollment target is 120 participants, below the 238-participant average among 70 other Tobacco Use Disorder trials with a reported enrollment target (50% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06218056, a Phase 2 study of Tobacco Use Disorder and Tobacco Smoking, is actively recruiting participants, sponsored by University of California, Los Angeles.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 120 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this research is to evaluate the efficacy of cannabidiol (CBD) in reducing cigarette smoking. Although there are safe and effective treatments for smoking cessation, not everyone who attempts smoking cessation is successful, even with these treatments. Relapse rates are high, leaving a need for new approaches. Despite justification to evaluate CBD for this indication, human research on the topic is scant. Larger, more extended studies are warranted and essential. The investigators will recruit participants from CRI-Help, Inc., a substance abuse treatment program in North Hollywood, where residents who indicate the desire to stop smoking are prohibited from using other cannabis products which would affect recruitment. The aims of this study are: 1. Evaluate the effects of CBD on changes in cigarette use throughout and following the trial. 2. Exploratory Aims. Measure plasma concentrations of CBD, N-arachidonoyl-ethanolamine (anandamide) and 2-arachidonoylglycerol (2-AG) throughout the trial. Participants who meet eligibility criteria will take part in a 56-day treatment phase during which they receive the study medication under supervision (CBD or placebo twice daily) and complete questionnaires on side effects, withdrawal, craving and mood symptoms. Blood, breath, and urine tests will also be performed throughout the study. Participants who complete the treatment will also be assessed at 1-month and 3-month follow up visits.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Cannabidiol (CBD) 800 mg
Study Locations (1)
California
- CRI-Help, Inc. - North Hollywood
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2024-10-31 |
| Est. Completion | 2026-12-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06218056
The ClinicalTrials.gov registry entry for NCT06218056 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 238-participant average among 70 other Tobacco Use Disorder trials with a reported enrollment target (50% lower). The listed sponsor is University of California, Los Angeles, which has 897 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Tobacco Use Disorder appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06218056 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT06218056 about?
NCT06218056 is a clinical study titled "Cannabidiol for Reducing Cigarette Use". The goal of this research is to evaluate the efficacy of cannabidiol (CBD) in reducing cigarette smoking. Although there are safe and effective treatments for smoking cessation, not everyone who attempts smoking cessation is successful, even with these treatments. Relapse rates are high, leaving a n...
What is the current status of trial NCT06218056?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 120 participants. The study started on 2024-10-31. Estimated completion is 2026-12-31.
What conditions does trial NCT06218056 study?
This clinical trial studies the following conditions: Tobacco Use Disorder, Tobacco Smoking, Tobacco Dependence.
What interventions are being tested in trial NCT06218056?
The interventions under investigation include: Placebo (DRUG), Cannabidiol (CBD) 800 mg (DRUG).
Who is sponsoring clinical trial NCT06218056?
This trial is sponsored by University of California, Los Angeles, which has 897 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06218056 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Tobacco Use Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Nicotine Regulation for Dual Users of E-cigarettes and Cigarettes
RECRUITING · Phase 2
-
Examining the Effects of Cytisinicline on Neural Substrates of Cigarette Cue-reactivity
RECRUITING · Phase 2
-
An fMRI Study of the Effects of Clavulanic Acid on Drug Addiction
RECRUITING · Phase 2
-
Neuroimaging Correlates and Feasibility of Transcranial Magnetic Stimulation (TMS) to Improve Smoking Cessation Outcomes in Veterans With Comorbid PTSD
RECRUITING · Phase 2
-
Off-Label Medications for Alcohol Use Disorder Among Patients With HIV: Pilot Study 2
RECRUITING · Phase 2
-
5-HT2A Agonist Psilocybin in the Treatment of Tobacco Use Disorder
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.